دورية أكاديمية
أعرض في EDS

Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.

التفاصيل البيبلوغرافية
العنوان: Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.
المؤلفون: Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, Martin ET, House S, Saade EA, Zimmerman RK, Gaglani M, Wernli KJ, Walter EB, Michaels MG, Staat MA, Weinberg GA, Selvarangan R, Boom JA, Klein EJ, Halasa NB, Ginde AA, Gibbs KW, Zhu Y, Self WH, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Weber ZA, Yang DH, Ball SW, Surie D, DeCuir J, Dawood FS, Moline HL, Toepfer AP, Clopper BR, Link-Gelles R, Payne AB, Chung JR, Flannery B, Lewis NM, Olson SM, Adams K, Tenforde MW, Garg S, Grohskopf LA, Reed C, Ellington S
مؤلفون مشاركون: CDC Influenza Vaccine Effectiveness Collaborators
المصدر: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Feb 29; Vol. 73 (8), pp. 168-174. Date of Electronic Publication: 2024 Feb 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: Atlanta, GA : U.S. Centers for Disease Control
Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control.
مواضيع طبية MeSH: Influenza Vaccines* , Influenza, Human*/epidemiology , Influenza, Human*/prevention & control, Adolescent ; Adult ; Humans ; Child ; Seasons ; Case-Control Studies ; Vaccine Efficacy
مستخلص: In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged ≥6 months with acute respiratory illness-associated medical encounters using a test-negative case-control study design. Among children and adolescents aged 6 months-17 years, VE against influenza-associated outpatient visits ranged from 59% to 67% and against influenza-associated hospitalization ranged from 52% to 61%. Among adults aged ≥18 years, VE against influenza-associated outpatient visits ranged from 33% to 49% and against hospitalization from 41% to 44%. VE against influenza A ranged from 46% to 59% for children and adolescents and from 27% to 46% for adults across settings. VE against influenza B ranged from 64% to 89% for pediatric patients in outpatient settings and from 60% to 78% for all adults across settings. These findings demonstrate that the 2023-24 seasonal influenza vaccine is effective at reducing the risk for medically attended influenza virus infection. CDC recommends that all persons aged ≥6 months who have not yet been vaccinated this season get vaccinated while influenza circulates locally.
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Emmanuel B. Walter reports institutional support from Pfizer, Moderna, Seqiris, Clinetic, and Najit Technologies Inc., consulting fees from ILiAD Biotechnologies, payment from the College of Diplomates of the American Board of Pediatric Dentistry, travel support from the American Academy of Pediatrics, and paid compensation for participation on the Vaxcyte Scientific Advisory Board. Yuwei Zhu reports participation on a Vanderbilt University Medical Center Data Safety Monitoring Board. Sara Y. Tartof reports institutional support from Pfizer and Genentech. Samantha M. Olson reports travel support from the Gates Foundation. Nicola P. Klein reports institutional support from Sanofi Pasteur, Merck, Pfizer, Seqirus, and GlaxoSmithKline; membership on an expert panel for a planned hepatitis E Phase II vaccine clinical trial among pregnant women in Pakistan; membership in Western States COVID-19 Scientific Safety Review Workgroup, Board on Population Health and Public Health Practice, National Academies of Science, Engineering and Medicine, and National Vaccine Advisory Committee Safety Subcommittee. Manjusha Gaglani reports receipt of honorarium for educational webinar presentation on respiratory viruses from the Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics, and serving as co-chair of the Infectious Diseases and Immunization Committee and Chair of the Texas Respiratory Syncytial Virus Taskforce, Texas Pediatric Society. Kevin W. Gibbs reports grants or contracts from the Department of Defense and the National Institutes of Health (NIH) and service as chair of the Vanderbilt University Medical Center Data Safety Monitoring Board. Adit A. Ginde reports institutional support from the NIH, the Department of Defense, AbbVie, and Faron Pharmaceuticals, consulting fees (paid to institution) from Biomeme and Seastar, and participation on data safety monitoring boards for the NIH and Emory University. Richard K. Zimmerman reports institutional support from the NIH and Sanofi Pasteur, and honorarium from Clinical Educational Alliance. Mary A. Staat reports institutional support from NIH, Pfizer, and Merck and royalties for Up-to-Date chapter on International Adoption. Stacey House reports institutional support from Seegene, Inc., Abbot, Healgen, Roche, CorDx, Hologic, Cepheid, Janssen, and Wondfo Biotech. Geoffrey A. Weinberg reports institutional support from the New York State Department of Health AIDS Institute, consulting fees from Inhalon Biopharma for participation on a Scientific Advisory Board, and honoraria from Merck & Company for textbook chapters. Marian G. Michaels reports institutional support from the National Institute on Allergy and Infectious Diseases and complimentary meeting attendance for presentation at the American Transplant Congress on respiratory viruses. Emily T. Martin reports receipt of grants or contracts from Merck. Natasha B. Halasa reports receipt of grants from Sanofi, Quidell, and Merck. Elie A. Saade reports institutional support from Protein Sciences Corporation, consulting fees, honoraria, and travel support from Johnson & Johnson and participation on a Johnson & Johnson Data Safety Monitoring Board. No other potential conflicts of interest were disclosed.
References: J Infect Dis. 2023 Jul 14;228(2):185-195. (PMID: 36683410)
MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):365-370. (PMID: 35271561)
Euro Surveill. 2024 Jan;29(2):. (PMID: 38214082)
MMWR Recomm Rep. 2021 Aug 27;70(5):1-28. (PMID: 34448800)
Clin Infect Dis. 2020 Jun 10;70(12):2496-2502. (PMID: 31344229)
Clin Infect Dis. 2020 Nov 5;71(8):e368-e376. (PMID: 31905401)
Clin Infect Dis. 2023 Dec 05;:. (PMID: 38051664)
Clin Infect Dis. 2022 Aug 24;75(1):e564-e571. (PMID: 35325923)
Clin Infect Dis. 2021 Aug 16;73(4):e947-e954. (PMID: 33502489)
Euro Surveill. 2024 Feb;29(8):. (PMID: 38390651)
معلومات مُعتمدة: U01 IP001189 United States IP NCIRD CDC HHS; U01 IP001182 United States IP NCIRD CDC HHS; UL1 TR001857 United States TR NCATS NIH HHS; U01 IP001150 United States IP NCIRD CDC HHS; U01 IP001181 United States IP NCIRD CDC HHS; U01 IP001184 United States IP NCIRD CDC HHS; U01 IP001158 United States IP NCIRD CDC HHS
فهرسة مساهمة: Investigator: AS Lauring, University of Michigan.; J Arndorfer, Intermountain Medical Center.; D Bride, Intermountain Medical Center.; ID Peltan, Intermountain Medical Center.; NM Mohr, University of Iowa.; DN Hager, Johns Hopkins University.; M Prekker, Hennepin County Medical Center.; A Mohamed, Montefiore Medical Center.; N Johnson, University of Washington.; J Steingrub, Baystate Medical Center.; A Khan, Oregon Health and Science University.; LW Busse, Emory University.; A Duggal, Cleveland Clinic.; JG Wilson, Stanford University.; N Qadir, University of California Los Angeles.; C Mallow, University of Miami.; JH Kwon, Washington University in St. Louis.; MC Exline, Ohio State University.; NI Shapiro, Beth Israel Deaconess Medical Center.; C Columbus, Baylor Scott & White Health and Texas A&M University School of Medicine.; IA Vaughan, Henry Ford Health.; JM Mosier, University of Arizona.; B Safdar, Yale University.; ES Harris, University of Utah.; JD Chappell, Vanderbilt University Medical Center.; LS Stewart, Vanderbilt University Medical Center.; SA Swan, Vanderbilt University Medical Center.; PA Piedra, Texas Children's Hospital and Baylor College of Medicine.; LC Sahni, Texas Children's Hospital and Baylor College of Medicine.; JA Englund, Seattle Children's Research Institute.; DM Zerr, Seattle Children's Research Institute.; RW Hickey, UPMC Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine.; JV Williams, UPMC Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine.; C Rohlfs, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine.; EP Schlaudecker, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine.; D Dosdos, Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine.; ME Moffatt, Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine.; JE Schuster, Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine.; K Weltmer, Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine.; PG Szilagyi, University of Rochester School of Medicine and Dentistry.; T Curley, Washington University School of Medicine in St. Louis.; J Mills, Washington University School of Medicine in St. Louis.; K Faryar, University Hospitals of Cleveland.; RA Salata, University Hospitals of Cleveland.; KM Geffel, University of Pittsburgh School of Medicine.; MP Nowalk, University of Pittsburgh School of Medicine.; K Murthy, Baylor Scott & White Health.; S Rose, Baylor Scott & White Health.; ME Smith, Baylor Scott & White Health.; B Wickersham, Kaiser Permanente Washington Health Research Institute.; BD Williamson, Kaiser Permanente Washington Health Research Institute.; NAB Bontrager, Duke Human Vaccine Institute.; OL Williams, Duke Human Vaccine Institute.; JL Kramer, Phoenix Children's Hospital.; L Nordstrom, Valleywise Health Medical Center.; AS Monto, University of Michigan School of Public Health.; IA Vaughn, Henry Ford Health.; M Dickerson, CDC.; C McLean, CDC.; EK Noble, CDC.; C Ray, CDC.; K Sumner, CDC.; I Essien, HealthPartners.; L Fletcher, HealthPartners.; P Heaton, HealthPartners.; S Kane, HealthPartners.; C McEvoy, HealthPartners.; S Thapa, HealthPartners.; G Vazquez-Benitez, HealthPartners.; C Bezi, Kaiser Permanente Southern California.; R Contreras, Kaiser Permanente Southern California.; GS Davis, Kaiser Permanente Southern California.; BJ Lewin, Kaiser Permanente Southern California.; P Mahale, Kaiser Permanente Southern California.; R Patrick, Kaiser Permanente Southern California.; L Qian, Kaiser Permanente Southern California.; E Rayens, Kaiser Permanente Southern California.; IAC Reyes, Kaiser Permanente Southern California.; DS Ryan, Kaiser Permanente Southern California.; SB Salas, Kaiser Permanente Southern California.; LS Sy, Kaiser Permanente Southern California.; M Yeh, Kaiser Permanente Southern California.; X Zeng, Kaiser Permanente Southern California.; B Fireman, Kaiser Permanente Northern California.; K Goddard, Kaiser Permanente Northern California.; J Hansen, Kaiser Permanente Northern California.; KB Jacobson, Kaiser Permanente Northern California.; J Timbol, Kaiser Permanente Northern California.; O Zerbo, Kaiser Permanente Northern California.; M Dunne, Westat.; Y Zhuang, Westat.
المشرفين على المادة: 0 (Influenza Vaccines)
تواريخ الأحداث: Date Created: 20240229 Date Completed: 20240304 Latest Revision: 20240619
رمز التحديث: 20240619
مُعرف محوري في PubMed: PMC10907036
DOI: 10.15585/mmwr.mm7308a3
PMID: 38421935
قاعدة البيانات: MEDLINE
الوصف
تدمد:1545-861X
DOI:10.15585/mmwr.mm7308a3